Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 11/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454293 | 0.91 | MAPK8 (0.43) | ACVR1MAPK8MAPK9MAPK10IRAK4 | |
| SCHEMBL4457136 | 0.88 | MAPK8 (0.46) | ACVR1MAPK8MAPK9MAPK10IRAK4 | |
| SCHEMBL4471182 | 0.84 | PTPN11 (0.34) | ACVR1IRAK4PTPN11LRRK2 | |
| SCHEMBL10227411 | 0.82 | ALK (0.34) | IRAK4PTPN11 | |
| SCHEMBL2753128 | 0.81 | PDPK1 (0.41) | ACVR1PTPN11 | |
| SCHEMBL4471444 | 0.79 | BRD4 (0.35) | IRAK4PTPN11 | |
| SCHEMBL4457985 | 0.79 | MAPK8 (0.54) | ACVR1MAPK8MAPK9MAPK10IRAK4 | |
| SCHEMBL4471983 | 0.78 | PSMB5 (0.39) | ACVR1LRRK2 | |
| SCHEMBL4472998 | 0.77 | PSMB5 (0.44) | LRRK2 | |
| SCHEMBL4458424 | 0.76 | PSMB5 (0.43) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPK13, MAPKAPK5 | ACVR1 4392/4885MAPK8 26/4885MAPK9 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.